Was macht Ultimovacs?
Unternehmensprofil
Ultimovacs AS operates as a pharmaceutical company. The firm engages in the development of novel immunotherapies against cancer. Its product, UV1, is a therapeutic cancer vaccine that activates the immune system to recognize telomerase. The company was founded on January 26, 2011 and is headquartered in Oslo, Norway.
Chart der Ultimovacs Aktie
Charttool öffnen
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.